Prime Core

  • Email
  • Linkedin
  • Twitter
  • Home
  • About Us
    • Team
    • Our Process
    • Wall of Success
  • Clients
  • Candidates
    • Tips
  • Prime-Core Blog
  • News
  • Contact Us

Posted by Ken Dropiewski

The CRISPR Debate: How a Patent Dispute is Threatening a Start Up Biotech Company

Editas Medicine, a start up medical biotech company, has raised more than $160 million prior to an eventual IPO to support its mission to develop a novel gene editing therapy to treat diseases. Unfortunately for Editas, the technology upon which it bases that therapy is now the subject of a patent dispute. Editas licensed that technology, which is formally known as “clustered regularly interspaced short palindromic repeats” or “CRISPR”, from a team of scientists affiliated with Harvard and MIT. A rival group of scientists from the University of California, however, have also laid claim to ownership of the technology. The rival ownership claims are now playing out before the United States Patent Office.

The competing ownership claims are driven, in major part, by recent changes in the U.S. Patent law, which now recognizes the first entity to file a patent application as the owner of the technology over the first to create the invention. The University of California team filed its patent application immediately before this law went into effect, and the MIT/Harvard team filed their application shortly thereafter.

Editas and other companies that sought to license the CRISPR technology stand to lose billions in revenue if their licensing rights to use that technology are deemed to be invalid. Apart from valuations and licensing rights, this situation raises two other issues that are relevant to the world of advanced gene therapy.

First, this technology can provide dramatic benefits to cure diseases. From a policy perspective, should the control of this technology be limited only to entities that can afford the billions of dollars that will be sought for license rights? Is there a public policy that extends those rights beyond a small group of entities who seek to control it?

Second, gene therapy brings to mind some of the worst examples of eugenics and population control. Ethicists continually warn of the slippery slope presented by gene therapy. If man can rearrange a person’s gene’s to ward off diseases, how else might that therapy be used?

Biotech and medical industry managers are not expected to have immediate answers to either of these questions. They need to remain aware of the challenges posed by gene therapy technologies and to have the foresight to manage those challenges when they arise in their own corporate environments.

Please contact us for more information on how keeping up with trends in the gene therapy industry can help you stay at the top of your field in the biotech and medical industries.  We look forward to the opportunity to help you excel in the future!

Follow me on Twitter @PrimeCoreSearch.

Filed Under: Prime-Core Blog Tagged With: biotechnology, Medical Device, recruiting

Company Profile

"Prime-Core, Inc is an Executive Search Firm that is passionate about helping med tech companies meet their Human Capital needs in order to foster a team dedicated to success. We believe there is a story behind every successful hire. One that stands the tests of time and truly transforms a good company to great company."

Recent Posts

  • Prime-Core Executive Search is now Part of McDermott & Bull
  • Endologix, Inc. Completes Patient Enrollment in the ELEVATE IDE Clinical Study
  • Can Getting the Flu Increase Your Risks for a Heart Attack?
  • LimFlow Completes Enrollment In U.S. Feasibility Study and Receives Breakthrough Device Status from FDA for Its Percutaneous Deep Vein Arterialization (pDVA) System
  • Stryker’s WEAVE Trial Demonstrates Positive Results of Endovascular Treatment for Patients With Intracranial Atherosclerotic Disease

Tags

advancement Approval biomedicine biotech biotechnology boitech California cancer cardiovascular disease Communication Costs cover letter Employment Empowerment Executive Search FDA generation gap generations goal setting healthcare Hiring HR interviewing jobs labor markets leadership management management skills Medical Companies Medical Device Medical Devices medical spending Motivation networking planning productivity recruiting Recuiting research resume social media talent team work force workplace

© 2019 · Prime-Core All Rights Reserved
13701 W Jewell Ave Suite 200-8
Lakewood, CO 80228.
Phone: 720-904-1777 | prime-core.com